SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services such as lead generation and content for other financial services institutions. The company was founded in 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is experiencing significant volatility and downward pressure as investors navigate a combination of bearish short-seller reports and broader macroeconomic concerns. The community remains deeply divided, with some actively accumulating shares during the dip based on insider buying, while others express frustration over persistent share dilution and the stock's failure to maintain momentum alongside the broader market.

Ondas, Inc. engages in the development, marketing, and sale of wireless radio systems for secure, wide area mission-critical business-to-business networks. It operates through the Ondas Networks and Ondas Autonomous Systems segments. The Ondas Networks segment provides wireless connectivity solutions enabling mission-critical Industrial Internet applications and services. The Ondas Autonomous Systems segment designs, develops, and markets commercial drone solutions via the Optimus System and Scout System. The company was founded on December 22, 2014 and is headquartered in West Palm Beach, FL.

Ondas Inc.

Ondas Inc

Ondas Inc. is seeing intense investor focus fueled by a flurry of strategic acquisitions, including Rotron Aerospace and 4M Defense, alongside a high-profile partnership with Palantir that has bolstered its status as an emerging defense prime. While the stock experiences significant intraday volatility and selling pressure attributed to warrant-related hedging, the community remains heavily bullish, fixated on the upcoming earnings report and the company's potential to secure major government defense contracts in an increasingly autonomous and drone-centric global threat landscape.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is experiencing extreme volatility driven by a massive insider share purchase by the CEO and growing investor anticipation regarding a potential partnership with OpenAI. The community remains deeply divided, with some traders viewing these catalysts as a long-term bottoming signal, while others criticize the company's executive compensation and struggle to reconcile the positive news with the stock's persistent intraday sell-offs.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is experiencing a volatile and high-momentum market debut as investors speculate on its drone autonomy software, which has gained attention for its reported real-world combat application. The community remains sharply divided, with some betting on a parabolic "low-float" squeeze driven by defense industry demand, while others caution against potential hype-driven instability and speculative valuations.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is trending as the community highlights recent long-term clinical data showing Briumvi's high efficacy and record-low relapse rates, fueling speculation about potential buyouts or increased market share. Investors are actively discussing the stock's growth potential versus its current price suppression, while closely watching for upcoming earnings and subcutaneous treatment updates.

Credo Technology Group Holding Ltd. engages in the development of connectivity solutions and products for the data infrastructure market. Its products include integrated circuits, active electrical cables, and SerDes chiplets. The company was founded by Chi Fung Cheng and Yat Tung Lam on 2008 and is headquartered in George Town, Cayman Islands.

Credo Technology Group Holding Ltd

Credo Technology is facing heightened volatility as traders weigh strong product milestones in AI data center infrastructure against recent insider selling and broader market rotation out of high-growth semiconductor plays. The community is actively debating the stock's future, with many interpreting recent sharp price swings as manipulative shakeouts while bulls focus on the company's long-term potential in AI connectivity.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly is trending as investors weigh strong demand for its GLP-1 franchise against intense market competition and analyst downgrades regarding valuation and addressable market size. The community remains highly focused on the company's upcoming pipeline catalysts, specifically the anticipated approval of its oral weight-loss drug, while debating whether recent share price volatility represents a buying opportunity or a correction from previous overvaluation.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is rallying toward all-time highs as investors pile in ahead of quarterly earnings, driven by intense demand for high-bandwidth memory (HBM) and recent announcements regarding significant manufacturing expansions in Taiwan. The community is heavily focused on the company's critical role in the AI infrastructure supply chain, with active debates centered on whether the stock remains undervalued despite its massive run or if it faces a potential post-earnings pullback.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending following a massive $27 billion AI infrastructure deal with Meta, which effectively cements its status as a leading hyperscaler. While the stock initially surged, it faced downward pressure due to the announcement of a $3.75 billion convertible senior notes offering, sparking intense debate among investors over whether the move represents necessary capital-intensive growth or dilutive overreach.

Talon Metals Corp. engages in the exploration and development of mineral properties. It holds interests in the Tamarack nickel-copper-cobalt and Trairão iron projects. The company was founded on April 5, 2005 and is headquartered in Road Town, British Virgin Islands.

Talon Metals Corp

Talon Metals is generating significant buzz as community members actively discuss its role as a critical domestic supplier for EV batteries and defense applications, bolstered by funding from the DOE and ongoing development at the Tamarack project. Investors are closely monitoring permitting milestones and technical chart behavior, with many viewing recent price dips as consolidation opportunities while anticipating major catalysts that could drive long-term value.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

HeartBeam Reports Fourth Quarter and Full Year 2025 Results

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, has reported its financial and operational results for the...

<ul><li>HeartBeam’s technology uniquely capable of assessing possible heart attacks outside of traditional clinical settings</li><li>ALIGN-ACS study expected to complete patient enrollment quickly</li><li>Milestone signifies key step toward future FDA indication expansion for heart attack assessment</li><li>Future indication expansion would unlock large market with over 20 million patients at risk of a heart attack</li></ul>SANTA CLARA, Calif.--(BUSINESS WIRE)-- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam, Inc.</a> (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the first patients have been enrolled in its ALIGN-ACS pilot study evaluating the HeartBeam System for heart attack detection. The first patients were enrolled by Prof. Dr. Vladan Vukcevic at the University Clinical Center of Serbia in Belgrade, Serbia. The initiation of the ALIGN-ACS pilot study represents a significant step toward collecting the data needed to support expanding the indication of the HeartBeam System beyond arrhythmia assessment to include heart attack assessment.Heart attacks remain the leading cause of death, with more than 20 million patients in the U.S. who are at risk. Patients often delay seeking care by 3–4 hours because symptoms can be vague or subtle, driving up mortality, complications, and cost of care. While a 12-lead ECG remains the standard of care for diagnosing a heart attack, there is no reliable method for physicians to assess possible heart attacks outside of a clinical setting. HeartBeam aims to fill this gap and shorten <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://newsroom.heart.org/news/acting-quickly-after-heart-attack-symptoms-start-can-be-a-heart-saver">“symptom-to-door” times</a>by enabling patients to record a clinical-grade ECG the moment symptoms begin, wherever they are. By capturing the heart’s electrical signals in 3D, from 3 non-coplanar dimensions, HeartBeam’s 3D ECG technology provides physicians with a high-fidelity, reliable way to assess possible heart attacks outside of a clinical setting.“Every minute matters during a heart attack, and early, accurate identification of a heart attack is essential to ensuring patients receive the care they need in a timely manner and improving outcomes,” said HeartBeam Scientific Advisory Board Chair C. Michael Gibson, MD, FRCP, FAHA, FSCAI, FACC, Interventional Cardiologist at Beth Israel Lahey and Professor of Medicine at Harvard Medical School. “HeartBeam’s technology has the potential to meaningfully change how quickly we evaluate patients by providing timely access to clinical-grade ECG data outside the hospital, enabling clinicians to accelerate triage decisions and intervene sooner.”The ALIGN-ACS pilot study is designed to enroll 100 patients presenting with chest pain in the emergency room (ER). Patients will be evaluated with both a standard 12-lead ECG and the HeartBeam device and both results will be compared with each patient’s final diagnosis at discharge. As the study is designed to enroll chest pain patients in the ER, enrollment is expected to progress quickly.The pilot study builds on multiple earlier <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/evidence#:~:text=Heart%20Attack%20Detection">proof of concept studies</a> demonstrating that a 3D ECG configuration similar to the HeartBeam device’s ability to detect heart attacks was similar in accuracy to a standard 12-lead ECG, including a study presented at the 2025 American Heart Association Scientific Sessions on the 3D approach. Learnings from the ALIGN-ACS pilot study will inform the design of a multicenter pivotal study that would serve as the basis of a future FDA submission.“HeartBeam was founded on the premise that since most heart attacks happen outside of a hospital, there should be a fast and easy way for patients and physicians to assess both symptoms and ECG data at home or anywhere,” said Robert Eno, Chief Executive Officer for HeartBeam. “The initiation of our pilot study for heart attack detection is a defining moment for HeartBeam as this is one of the largest clinical opportunities in cardiology. Our platform is uniquely positioned to deliver clinical-grade ECG insights at the moment symptoms occur and facilitate more timely action to close the ‘symptom-to-door’ gap.”This milestone aligns directly with HeartBeam’s key long-term growth initiatives, which also include the limited launch of the FDA-cleared HeartBeam System for arrhythmia assessment, ongoing development of the Company’s working-prototype 12-lead ECG patch monitor and advancement of its AI program. These initiatives collectively position HeartBeam to advance its vision for more accessible and intelligent cardiac care.About HeartBeam, Inc.HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam received FDA clearance for arrhythmia assessment for its 3D ECG technology in December 2024 and for its 12-Lead ECG synthesis software in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam.com</a>.Forward-Looking StatementsAll statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.sec.gov/">www.sec.gov</a>. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.1Cleared Indications for UseThe HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/indications">https://www.heartbeam.com/indications</a> for details on the intended use of its technology.MKT-109 v1&nbsp;View source version on businesswire.com: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260305231175/en/">https://www.businesswire.com/news/home/20260305231175/en/</a>Media Contact: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@heartbeam.com">media@heartbeam.com</a> Investor Relations Contact: Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:BEAT@mzgroup.us">BEAT@mzgroup.us</a> <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.mzgroup.us/">www.mzgroup.us</a>Source: HeartBeam, Inc.Released March 5, 2026Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

HeartBeam Announces First Patient Enrollments in Heart Attack Detection Pilot Study

HeartBeam starts ALIGN-ACS study to validate 3D ECG for home-based heart attack detection.

Others

<ul><li>Accelerates development of personalized cardiac AI on the HeartBeam platform for wellness and clinical applications, including assessing heart attack risk</li><li>Combines Mount Sinai’s world-class AI and clinical expertise with HeartBeam’s groundbreaking 3D ECG signal collection technology</li><li>HeartBeam is the only platform capable of collecting 12-lead ECG data from patients anytime, anywhere, over time – extending access beyond traditional clinical settings</li><li>Positions HeartBeam to expand from symptom-based cardiac rhythm monitoring into AI-enabled disease assessment and management</li></ul>SANTA CLARA, Calif.--(BUSINESS WIRE)-- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam, Inc.</a> (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New York to accelerate the joint development and validation of next-generation AI-ECG algorithms. The collaboration will leverage HeartBeam’s patented ECG platform, which captures the heart’s electrical activity from 3 non-coplanar dimensions. The partnership marks a significant milestone in the Company’s long-term strategy to build an ecosystem around its platform and strengthen its leadership in AI-enabled cardiac monitoring.A core value driver of the collaboration is HeartBeam’s differentiated ability to generate longitudinal, high-fidelity synthesized 12-lead ECG datasets from patients in the home setting—data that has historically been inaccessible to AI development. This creates a foundation for developing increasingly personalized algorithms earlier in the care journey and enabling 12-lead ECG assessments in real-world settings, supporting both wellness use cases and clinically relevant assessments, such as heart attack risk.The combination of HeartBeam’s continuously expanding dataset and Mount Sinai’s clinically annotated 12-lead ECG data can accelerate the training and validation of various AI models. Over time, this collaboration will result in a data engine that is expected to support the development of increasingly personalized algorithms—positioning HeartBeam to expand into new clinical indications and reimbursement pathways.“We believe expanding access to 12-lead ECG data assessment beyond the clinic is one of the biggest opportunities,” said Robert Eno, Chief Executive Officer of HeartBeam. “By pairing our ability to gather high-fidelity real-world ECG data with Mount Sinai’s extensive clinical data resources and AI expertise, we are creating a differentiated cardiac intelligence engine that can scale beyond traditional care settings and broaden the reach of predictive cardiology, ultimately expanding our clinical and commercial opportunity.”Under the collaboration, HeartBeam’s in-house AI team led by Lance Myers, PhD, a leading authority on AI applications in biosensor technologies, will work closely with Mount Sinai researchers to develop, train and validate a suite of advanced AI-ECG algorithms intended for deployment onto the HeartBeam platform. Joshua Lampert, MD, FACC, a pioneer in AI-ECG and cardiovascular deep learning research and clinician recognized for his excellence in patient care, Vivek Reddy, MD, an internationally renowned electrophysiologist and innovator, and Girish N. Nadkarni, MD, MPH, the Chief AI Officer of the Mount Sinai Health System and Chair of the Windreich Department of Artificial Intelligence and Human Health at the Icahn School of Medicine at Mount Sinai, will help guide the scientific and clinical development of the partnership.“While AI-ECG has rapidly progressed as a field over recent years, there is room for improvement in the portability and scalability of such algorithms beyond acquisition devices that require complex multi-electrode systems. Additionally, current approaches struggle to leverage deep learning inference opportunities outside of traditional health care settings, which is where dynamic changes to cardiovascular health first start before patients present for care. The collaboration addresses these vital needs. By combining deep learning tools with the ability to record full 3-dimensional cardiac electrical activity without cables, we can provide clinically meaningful and operationally pragmatic models at scale regardless of environment,” said Dr. Lampert, Cardiac Electrophysiologist, Medical Director of Machine Learning for Mount Sinai Fuster Heart Hospital and Director of Cardiovascular Artificial Intelligence for the Windreich Department of Artificial Intelligence and Human Health at Mount Sinai.Pairing HeartBeam’s innovative hardware and approach to cardiac waveform engineering with Mount Sinai’s advanced AI and clinical expertise creates a powerful foundation for developing tools that dynamically meet modern patient and clinician needs wherever they are.“Heart disease doesn’t only show up during a brief visit to the clinic. This collaboration gives us an opportunity to bring powerful clinical-grade heart monitoring into patients’ daily lives,” said Dr. Nadkarni. “By combining advanced AI with HeartBeam’s ability to capture full 12-lead ECG signals from home over time, we can study the heart in ways that simply haven’t been possible before—helping clinicians detect risk earlier and guide care more precisely.”“This collaboration addresses an important need by leveraging deep learning and 3-dimensional waveform data for scalable diagnostic and predictive purposes, allowing insights beyond even expert human ability,” added Dr. Reddy, who serves as the Director of Cardiac Arrhythmia Services for Mount Sinai Health System.Together, the two organizations aim to accelerate the development of high-value algorithms that can be deployed broadly across HeartBeam’s platform. These AI models may include patient-relevant wellness insights, condition-focused assessments, and applications for chronic condition management. By enabling AI models to operate on longitudinal, real-world synthesized 12-lead ECG data rather than isolated clinical snapshots, the collaboration has the potential to significantly expand the addressable market for AI-driven cardiac monitoring. The collaboration could unlock new opportunities in preventive cardiology, chronic disease management, and remote patient monitoring—further reinforcing HeartBeam’s position as a leader in cardiac intelligence platforms.About the Mount Sinai Health SystemMount Sinai Health System is one of the largest academic medical systems in the New York metro area, with 48,000 employees working across seven hospitals, more than 400 outpatient practices, more than 600 research and clinical labs, a school of nursing, and a leading school of medicine and graduate education. Mount Sinai advances health for all people, everywhere, by taking on the most complex health care challenges of our time—discovering and applying new scientific learning and knowledge; developing safer, more effective treatments; educating the next generation of medical leaders and innovators; and supporting local communities by delivering high-quality care to all who need it.Through the integration of its hospitals, labs, and schools, Mount Sinai offers comprehensive health care solutions from birth through geriatrics, leveraging innovative approaches such as artificial intelligence and informatics while keeping patients’ medical and emotional needs at the center of all treatment. The Health System includes approximately 9,000 primary and specialty care physicians and 10 free-standing joint-venture centers throughout the five boroughs of New York City, Westchester, Long Island, and Florida. Hospitals within the System are consistently ranked by Newsweek’s® “The World’s Best Smart Hospitals, Best in State Hospitals, World Best Hospitals and Best Specialty Hospitals” and by U.S. News &amp; World Report's® “Best Hospitals” and “Best Children’s Hospitals.” The Mount Sinai Hospital is on the U.S. News &amp; World Report® “Best Hospitals” Honor Roll for 2025-2026.For more information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.mountsinai.org/">https://www.mountsinai.org/</a> or find Mount Sinai on <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.facebook.com/mountsinainyc?utm_medium=cpc&amp;utm_source=google&amp;utm_content=googlesem&amp;utm_campaign=mshs-respiratoryinstitute">Facebook</a>, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.instagram.com/mountsinainyc/?hl=en">Instagram</a>, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.linkedin.com/company/mountsinainyc/">LinkedIn</a>, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://twitter.com/mountsinainyc?utm_medium=cpc&amp;utm_source=google&amp;utm_content=googlesem&amp;utm_campaign=mshs-respiratoryinstitute">X</a>, and <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.youtube.com/mountsinainy">YouTube</a>.About HeartBeam, Inc.HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-Lead ECG synthesis software in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam.com</a>.Forward-Looking StatementsAll statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.sec.gov/">www.sec.gov</a>. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.1Cleared Indications for UseThe HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/indications">https://www.heartbeam.com/indications</a> for details on the intended use of its technology.&nbsp;View source version on businesswire.com: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260310761343/en/">https://www.businesswire.com/news/home/20260310761343/en/</a>Media Contact: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@heartbeam.com">media@heartbeam.com</a>Investor Relations Contact: Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:BEAT@mzgroup.us">BEAT@mzgroup.us</a> <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.mzgroup.us/">www.mzgroup.us</a>Source: HeartBeam, Inc.Released March 10, 2026Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

HeartBeam and Mount Sinai Announce Strategic AI Collaboration to Bring Clinical-Grade Heart Monitoring into the Home

HeartBeam and Mount Sinai partner to develop AI-ECG algorithms for remote heart attack assessment.

<ul><li>Marks HeartBeam’s transition to commercial company</li><li>Rapidly growing practice and highly engaged member population to enable broad adoption</li><li>Enables efficient scaling of additional preventive cardiology and executive health programs</li><li>Establishes initial foothold in structured direct pay healthcare segment representing 5 million patients</li></ul>SANTA CLARA, Calif.--(BUSINESS WIRE)-- <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam, Inc.</a> (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced a commercial partnership with <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://clearcardio.com/">ClearCardio™</a>, a leading preventive cardiology practice that has served thousands of patients through advanced heart health screening and personalized prevention programs. In addition to serving as HeartBeam’s first commercial customer, ClearCardio also plans to make an investment in HeartBeam, reflecting strong strategic alignment.The partnership includes an initial staged rollout to ensure a seamless patient and physician experience, and plans for broader expansion to thousands of highly engaged members across multiple U.S. geographies. ClearCardio offers its members a cardiac prevention program to monitor cardiac risk factors and will incorporate HeartBeam’s synthesized 12-lead ECG technology into the program for arrhythmia assessment.HeartBeam’s patented cable-free 3D ECG technology captures the heart’s electrical signals in three non-coplanar dimensions and synthesizes them into a 12-lead ECG. This allows patients to obtain a high-fidelity, clinical-grade ECG reading for their arrhythmia from the comfort of home, or wherever they happen to be, representing a new level of convenience and peace of mind.“ClearCardio was founded on the belief that proactive care, including earlier detection and continuous vigilance, can meaningfully change patient outcomes,” said John Osborne, MD, PhD, Chief Medical Officer of ClearCardio, “HeartBeam’s synthesized 12-lead ECG technology for arrhythmia assessments fits directly into that mission by giving our patients an unprecedented ability to capture meaningful cardiac data whenever symptoms occur while being connected directly to our physicians. This is a major step forward in preventive cardiology.”This collaboration highlights HeartBeam’s fit within a premium, innovation-first segment where patient engagement is high, new product adoption moves quickly, and physicians seek differentiated solutions for patients who are willing to pay for proactive peace of mind. The agreement positions HeartBeam to replicate this model across additional concierge care networks, preventive cardiology groups, and executive health programs nationwide. Additionally, this collaboration supports the validation of HeartBeam’s pricing and subscription-based business model.“ClearCardio becoming our first commercial customer sends a clear message to the market. We believe HeartBeam’s technology is ready, the need is real, and the demand is building,” stated Robert Eno, Chief Executive Officer at HeartBeam. “We believe this is the beginning of a new growth phase for HeartBeam and the first of many milestones to come across our key growth initiatives.”The initial agreement with ClearCardio is structured as a Letter of Intent (LOI), outlining the commercial terms and a collaborative rollout plan, including a subscription fee per patient. During the initial deployment phase, HeartBeam and ClearCardio intend to negotiate and execute a definitive agreement.This commercial milestone aligns directly with HeartBeam’s long-term growth strategy, which includes the limited launch of the FDA-cleared HeartBeam System for arrhythmia assessment, future indication for heart attack assessment, ongoing development of the Company’s working-prototype 12-lead ECG patch monitor and advancement of its AI program. These initiatives collectively position HeartBeam to advance its vision for more accessible and intelligent cardiac care.About ClearCardioClearCardio, LLC is a leading preventive cardiology practice that has served thousands of patients through advanced heart health screening and personalized prevention programs. At the forefront of cardiovascular innovation, ClearCardio specializes in early detection and precision treatment of arterial plaque—the root cause of heart attacks—using cutting-edge AI-powered imaging and non-invasive diagnostics. Working with high-performing professionals, executives, and public safety leaders who know their health impacts more than just themselves, ClearCardio physicians help members detect cardiac disease early, quantify personal risk with clarity and treat the root cause, not just the symptoms. Visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.clearcardio.com/">www.clearcardio.com</a> for more information.About HeartBeam, Inc.HeartBeam, Inc. (NASDAQ: BEAT) is a medical technology company dedicated to transforming the detection and monitoring of critical cardiac conditions. The Company is creating the first-ever cable-free device capable of collecting ECG signals in 3D, from three non-coplanar directions, and synthesizing the signals into a 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is to deliver actionable heart intelligence. Physicians will be able to identify cardiac health trends and acute conditions and direct patients to the appropriate care – all outside of a medical facility, thus redefining the future of cardiac health management. HeartBeam’s 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024 and the 12-lead ECG synthesis software in December 20251. The Company holds over 20 issued patents related to technology enablement. For additional information, visit <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/">HeartBeam.com</a>.Forward-Looking StatementsAll statements in this release that are not based on historical fact are "forward-looking statements." While management has based any forward-looking statements included in this release on its current expectations, the information on which such expectations were based may change. Forward-looking statements involve inherent risks and uncertainties which could cause actual results to differ materially from those in the forward-looking statements, as a result of various factors including those risks and uncertainties described in the Risk Factors and in Management’s Discussion and Analysis of Financial Condition and Results of Operations sections of our Forms 10-K, 10-Q and other reports filed with the SEC and available at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.sec.gov/">www.sec.gov</a>. We urge you to consider those risks and uncertainties in evaluating our forward-looking statements. We caution readers not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Except as otherwise required by the federal securities laws, we disclaim any obligation or undertaking to publicly release any updates or revisions to any forward-looking statement contained herein (or elsewhere) to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.1Cleared Indications for UseThe HeartBeam System with 12-Lead ECG synthesis software for arrhythmia assessment received FDA clearance in December 2025. Refer to the Company’s Cleared Indications for Use at <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.heartbeam.com/indications">https://www.heartbeam.com/indications</a> for details on the intended use of its technology.&nbsp;View source version on businesswire.com: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.businesswire.com/news/home/20260304586980/en/">https://www.businesswire.com/news/home/20260304586980/en/</a>Media Contact: <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@heartbeam.com">media@heartbeam.com</a>Investor Relations Contact: Chris Tyson Executive Vice President MZ North America Direct: 949-491-8235 <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="mailto:BEAT@mzgroup.us">BEAT@mzgroup.us</a> <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="http://www.mzgroup.us/">www.mzgroup.us</a>Source: HeartBeam, Inc.Released March 4, 2026Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

HeartBeam Announces First Commercial Customer as ClearCardio Brings Groundbreaking 12-Lead ECG Technology to High-Growth Preventive Cardiology Market

HeartBeam partners with ClearCardio to commercialize its 3D ECG tech for preventive cardiac care.

Strategic Partnerships and Platform Plays Power New Momentum Across Tech and Healthcare

Markets open the session with strategic partnerships, infrastructure consolidation, and breakthrough technologies dominating the corporate news cycle; several companies are positioning themselves at the intersection of innovation and scalable commercialization. $INKT, $VTAK, $KBLB, $APP, $BEAT, $SGN, $STGW

Heartbeam Stock Jumps After AI Collaboration With Mount Sinai

HeartBeam shares are trading higher Tuesday following a partnership with Mount Sinai to accelerate next-gen AI-ECG algorithms.read more...

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced a strategic collaboration with the Icahn...

HeartBeam to Attend Investor and Industry Conferences in March, Focused on Providing Updates on Commercial Launch and Unveiling 12-Lead ECG Extended Wear Patch

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that management will attend key investor and...

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, today announced that the first patients have been enrolled in...

HeartBeam to Host Fourth Quarter Full Year 2025 Results Conference Call on Thursday, March 12, 2026 at 4:30 p.m. Eastern Time

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, will hold a conference call on Thursday, March 12, 2026 at...

HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology. Its electrocardiogram (ECG) collection device provides physicians with cardiac diagnostic information for a patient that is outside of a medical institution. The device sends ECG signals to the patient's smartphone and on to a cloud-based software expert system. The company was founded by Branislav Vajdic in 2015 and is headquartered in Santa Clara, CA.

BEAT
HeartBeam Inc

Feed

News

Sentiment

Fundamentals

Info

Latest BEAT News

BEATHeartBeam Inc